Literature DB >> 10882689

Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells.

G Gargala1, A Delaunay, X Li, P Brasseur, L Favennec, J J Ballet.   

Abstract

The effects of nitazoxanide and its metabolites, tizoxanide and tizoxanide glucuronide, on the development of the asexual and sexual stages of Cryptosporidium parvum in differentiated human enterocytic HCT-8 cells were evaluated in a quantitative alkaline phosphatase immunoassay. Nitazoxanide, tizoxanide and tizoxanide glucuronide were inhibitory for up to 46 h when added after sporozoite invasion (MIC50 1.2, 22.6 and 2.2 mg/L, respectively). Tizoxanide had only limited activity, but nitazoxanide and tizoxanide glucuronide strongly inhibited asexual and sexual stages, respectively.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10882689     DOI： 10.1093/jac/46.1.57

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  26 in total

Review 1.  Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.

Authors:  Vahab Ali; Tomoyoshi Nozaki
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Transient neonatal Cryptosporidium parvum infection triggers long-term jejunal hypersensitivity to distension in immunocompetent rats.

Authors:  Rachel Marion; Asiya Baishanbo; Gilles Gargala; Arnaud François; Philippe Ducrotté; Celia Duclos; Jean Fioramonti; Jean Jacques Ballet; Loïc Favennec
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.

Authors:  Suresh Kumar Gorla; Nina N McNair; Guangyi Yang; Song Gao; Ming Hu; Venkatakrishna R Jala; Bodduluri Haribabu; Boris Striepen; Gregory D Cuny; Jan R Mead; Lizbeth Hedstrom
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

4.  A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium.

Authors:  Anindita Mukerjee; Pinar Iyidogan; Alejandro Castellanos-Gonzalez; José A Cisneros; Daniel Czyzyk; Amalendu Prakash Ranjan; William L Jorgensen; A Clinton White; Jamboor K Vishwanatha; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2015-04-04       Impact factor: 2.823

5.  Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.

Authors:  Vidya P Kumar; Jose A Cisneros; Kathleen M Frey; Alejandro Castellanos-Gonzalez; Yiqiang Wang; Aleem Gangjee; A Clinton White; William L Jorgensen; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2014-07-24       Impact factor: 2.823

6.  Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development.

Authors:  G Gargala; A Baishanbo; L Favennec; A François; J J Ballet; J-F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

7.  Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro.

Authors:  Xiaomin Cai; Keith M Woods; Steve J Upton; Guan Zhu
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

8.  Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.

Authors:  Kovi Bessoff; Adam Sateriale; K Kyungae Lee; Christopher D Huston
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

9.  Novel non-active site inhibitor of Cryptosporidium hominis TS-DHFR identified by a virtual screen.

Authors:  W Edward Martucci; Marina Udier-Blagovic; Chloe Atreya; Oladapo Babatunde; Melissa A Vargo; William L Jorgensen; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2008-11-20       Impact factor: 2.823

10.  Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study.

Authors:  Yvonne Guttner; Helen M Windsor; Charlie H Viiala; Leon Dusci; Barry J Marshall
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.